|
Galapagos is a Belgian
clinical-stage biotechnology company specialized in the discovery and
development of small molecule medicines with novel modes of action. Our mission
is to develop first-in-class medicines based on the discovery of novel targets.
Using human primary cells and patient cells, we discover which proteins
(‘targets’) play a key role in causing diseases such as rheumatoid arthritis,
inflammatory bowel disease and fibrosis.
Galapagos then aims to develop small
molecules that inhibit these targets, restore the balance and thereby
positively influence the course of the disease. This approach addresses the
disease rather than just treating the symptoms. Galapagos’ aim is to make a
lasting positive contribution to society through discovery of breakthrough
therapies for diseases with large unmet medical need.
|
